1 |
HIRATA K I. New evidence of probucol on cardiovascular events[J]. J Atheroscler Thromb, 2021, 28(2):97-99. DOI:10.5551/jat.ED155 .
|
2 |
YAMASHITA S, MASUDA D, OHAMA T, et al. Rationale and design of the PROSPECTIVE trial: probucol trial for secondary prevention of atherosclerotic events in patients with prior coronary heart disease[J]. J Atheroscler Thromb, 2016, 23(6):746-756. DOI:10.5551/jat.32813 .
|
3 |
LIU J C, LI M H, LU H, et al. Effects of probucol on restenosis after percutaneous coronary intervention: a systematic review and meta-analysis[J]. PLoS One, 2015, 10(4): e0124021. DOI:10.1371/journal.pone.0124021 .
|
4 |
HIGASHI K, MORI A, SAKAMOTO K, et al. Probucol slows the progression of cataracts in streptozotocin-induced hyperglycemic rats[J]. Pharmacology, 2019, 103(3-4):212-219. DOI:10.1159/000496055 .
|
5 |
JUNG Y S, PARK J H, KIM H, et al. Probucol inhibits LPS-induced microglia activation and ameliorates brain ischemic injury in normal and hyperlipidemic mice[J]. Acta Pharmacol Sin, 2016, 37(8):1031-1044. DOI:10.1038/aps.2016.51 .
|
6 |
HAN L M, YANG Q S, SHEN T, et al. Lymphatic transport of orally administered probucol-loaded mPEG-DSPE micelles[J]. Drug Deliv, 2016, 23(6):1955-1961. DOI:10.3109/10717544.2015.1028600 .
|
7 |
QIAN Y W, CHEN G G, WANG J, et al. Preparation and evaluation of probucol-phospholipid complex with enhanced bioavailability and No food effect[J]. AAPS Pharmscitech, 2018, 19(8):3599-3608. DOI:10.1208/s12249-018-1157-2 .
|
8 |
GERSHKOVICH P, HOFFMAN A. Uptake of lipophilic drugs by plasma derived isolated chylomicrons: linear correlation with intestinal lymphatic bioavailability[J]. Eur J Pharm Sci, 2005, 26(5):394-404. DOI:10.1016/j.ejps.2005.07.011 .
|
9 |
YÁÑEZ J A, WANG S W J, KNEMEYER I W, et al. Intestinal lymphatic transport for drug delivery[J]. Adv Drug Deliv Rev, 2011, 63(10-11):923-942. DOI:10.1016/j.addr.2011.05.019 .
|
10 |
BEG S, ALAM M N, AHMAD F J, et al. Chylomicron mimicking nanocolloidal carriers of rosuvastatin calcium for lymphatic drug targeting and management of hyperlipidemia[J]. Colloids Surf B Biointerfaces, 2019, 177:541-549. DOI:10.1016/j.colsurfb.2019.02.039 .
|
11 |
HOKKANEN K, TIRRONEN A, YLÄ-HERTTUALA S. Intestinal lymphatic vessels and their role in chylomicron absorption and lipid homeostasis[J]. Curr Opin Lipidol, 2019, 30(5):370-376. DOI:10.1097/MOL.0000000000000626 .
|
12 |
KIM H, SEONG I, RO J, et al. Enhanced association of probucol with chylomicron by pharmaceutical excipients: an in vitro study[J]. Drug Dev Ind Pharm, 2015, 41(7):1073-1079. DOI:10.3109/03639045.2014.927479 .
|
13 |
张笑瑞, 曹静, 吴倩倩, 等. 大鼠肠系膜淋巴液持续引流新方法的初步建立[J]. 实验动物与比较医学, 2022, 42(4):267-274. DOI:10.12300/j.issn.1674-5817.2022.024 .
|
|
ZHANG X R, CAO J, WU Q Q, et al. A preliminary method for continuous drainage of mesenteric lymph fluid in rat[J]. Laboratory Animal and Comparative Medicine, 2022, 42(4):267-274. DOI:10.12300/j.issn.1674-5817.2022.024 .
|
14 |
ALEXANDER J S, GANTA V C, JORDAN P A, et al. Gastrointestinal lymphatics in health and disease[J]. Pathophysiology, 2010, 17(4):315-335. DOI:10.1016/j.pathophys. 2009.09.003 .
|
15 |
HYEONGMIN K, YEONGSEOK K, JAEHWI L E. Liposomal formulations for enhanced lymphatic drug delivery[J]. Asian J Pharm Sci, 2013(2):96-103.
|
16 |
MARWAHA R K, DABAS A. Bioavailability of nanoemulsion formulations vs conventional fat soluble preparations of cholecalciferol (D3) - An overview[J]. J Clin Orthop Trauma, 2019, 10(6):1094-1096. DOI:10.1016/j.jcot.2019.07.014 .
|
17 |
ZHANG Y M, ZHANG S K, CUI N Q. Intravenous infusion of mesenteric lymph from severe intraperitoneal infection rats causes lung injury in healthy rats[J]. World J Gastroenterol, 2014, 20(16):4771-4777. DOI:10.3748/wjg.v20.i16.4771 .
|
18 |
CHAMPAGNE D, PEARSON D, DEA D, et al. The cholesterol-lowering drug Probucol increases apolipoprotein E production in the hippocampus of aged rats: implications for Alzheimer's disease[J]. Neuroscience, 2003, 121(1):99-110. DOI:10.1016/S0306-4522(03)00361-0 .
|
19 |
BROCKS D R, DAVIES N M. Lymphatic drug absorption via the enterocytes: pharmacokinetic simulation, modeling, and considerations for optimal drug development[J]. J Pharm Pharm Sci, 2018, 21(1s):254s-270s. DOI:10.18433/jpps30217 .
|
20 |
LI J, YANG Y, ZHAO M H, et al. Improved oral bioavailability of probucol by dry media-milling[J]. Mater Sci Eng C, 2017, 78:780-786. DOI:10.1016/j.msec.2017.04.141 .
|
21 |
SCHÖNFELD P, WOJTCZAK L. Short- and medium-chain fatty acids in energy metabolism: the cellular perspective[J]. J Lipid Res, 2016, 57(6):943-954. DOI:10.1194/jlr.R067629 .
|
22 |
TANOUS D, BRÄSEN J H, CHOY K, et al. Probucol inhibits in-stent thrombosis and neointimal hyperplasia by promoting re-endothelialization[J]. Atherosclerosis, 2006, 189(2):342-349. DOI:10.1016/j.atherosclerosis.2006.01.025 .
|
23 |
KOSTIK V, MEMETI S, BAUER B. Fatty acid composition of edible oils and fats[J]. J Hyg Eng Des, 2013, 4: 112-116.
|